REG - EKF Diagnostics Hldg - Share Buyback

EKF Diagnostics HoldingsAnnouncement

Yesterday 12:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251015:nRSO5218Da&default-theme=true

RNS Number : 5218D  EKF Diagnostics Holdings PLC  15 October 2025

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

Share Buyback

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics
business, announces that it has purchased a total of 709,193 of its ordinary
shares of 1p each in the capital of the Company ("Ordinary Shares") at a
weighted average price of 28 pence per share. The Ordinary Shares purchased
will be held in treasury.

 

Aggregated information

 

 Date of purchase                       14 October 2025
 Number of Ordinary Shares purchased    709,193
 Highest price paid per Ordinary Share  28p
 Lowest price paid per Ordinary Share   28p
 Volume weighted average price paid     28p

 

 Transaction details

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market
Abuse Regulation) (which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018), a detailed breakdown of individual
trades is available below:

 

 Number of Ordinary Shares purchased  Transaction price (GBp)  Time of transaction  Trading venue
 500,000                              28p                      11:19:37             AIMX
 209,193                              28p                      15:51:08             AIMX

 

Total voting rights

 

Following the purchase, the Company's total issued share capital will consist
of 449,093,790 Ordinary Shares, of which 709,193 Ordinary Shares are held in
treasury. Therefore, the total number of Ordinary Shares carrying voting
rights will be 448,384,597. This figure may be used by shareholders as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
Company under the FCA's Disclosure Guidance and Transparency Rules.

 

PDMR dealing

 

As part of the buyback and within the above aggregate purchase, EKF acquired
209,193 Ordinary Shares in total at a price of 28 pence per Ordinary Share
from Harwood as investment manager to Oryx International Growth Fund Limited
("Oryx") and North Atlantic Smaller Companies Investment Trust PLC ("NASCIT").
EKF acquired 69,731 and 139,462 Ordinary Shares from Oryx and NASCIT
respectively. Harwood has facilitated this transaction solely in order to
ensure that the aggregate indirect beneficial interest of Mr. Mills remains at
approximately the same level and in any event does not exceed 30% of the
prevailing total voting rights in the Company following any repurchases.

 

Following the above sale of Ordinary Shares by Oryx and NASCIT to the Company,
Mr. Mills' aggregate indirect interest in the Company is 132,224,000 Ordinary
Shares.

 

Additional disclosures relating to this PDMR dealing are detailed below.

 

 

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018).

 

 

The person responsible for arranging the release of this Announcement

on behalf of the Company is Julian Baines, Executive Chair.

 

 

 EKF Diagnostics Holdings plc                                www.ekfdiagnostics.com (http://www.ekfdiagnostics.com)
 Julian Baines, Executive Chair                               via Walbrook PR
 Gavin Jones, Chief Executive Officer
                                                                                           Tel: +44 (0)20 7496 3000

 Singer Capital Markets (Nominated Adviser & Broker)
 Phil Davies / Oliver Platts

 Walbrook PR Limited              Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com (mailto:ekf@walbrookpr.com)
 Paul McManus / Alice Woodings    Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
(http://www.ekfdiagnostics.com) )

 

EKF is an AIM-listed global diagnostics business focussed on:

 

 ●    Point-of-Care analysers in the key areas of Hematology and Diabetes
 ●    Life Sciences services provide specialist manufacture of enzymes and custom
      products for use in diagnostic, food and industrial applications.

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing
sites across the US and Germany, selling into over 120 countries world-wide.

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Christopher Mills

 2    Reason for the notification

 a)   Position/status                                              Non-Executive Director

 b)   Initial notification /Amendment                              Initial Notification

 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor
 a)   Name                                                         EKF Diagnostics Holdings plc
 b)   LEI                                                          213800DXTF3EAUK1AR05

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 1 pence each

      Identification code                                          GB0031509804

 b)   Nature of the transaction                                    Disposal of Ordinary Shares

 c)   Price(s) and volume(s)

                                                                                     Price(s)          Volume(s)
                                                                                     28p               209,193

 d)   Aggregated information

      - Aggregated volume                                          n/a

      - Price

 e)   Date of the transaction

                                                                   14 October 2025

 f)   Place of the transaction                                     London Stock Exchange, AIMX

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFFWFFIEISEES



            Copyright 2019 Regulatory News Service, all rights reserved